Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years. Nogapendekin alfa inbakicept ...
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution. In this ...
The minimally invasive surgical therapy is approved for the treatment of lower urinary tract symptoms secondary to BPH. The FDA has approved the Optilume BPH Catheter System for the treatment of lower ...
Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with ...
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study. Jeffrey M. Spier, MD, reviews evidence on ...
"Pediatric-type cancer diagnoses in adults are rare, and there are important differences in caring for children with genitourinary malignancies compared with adults," write the authors.
This digital series features articles and videos with insights and expert viewpoints on PSMA-PET and the evolving imaging paradigm that is revolutionizing the diagnosis and treatment of patients with ...
Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision. Overall, a ...
Low baseline IsoPSA index correlates with reduced risk of clinically significant prostate cancer in patients with elevated PSA levels. Patients with low IsoPSA index showed lower rates of prostate ...
TLX250-CDx aims to address unmet needs in ccRCC imaging, with a potential U.S. commercial launch in 2025. The FDA's initial concerns were related to sterility assurance, not the agent's safety or ...
From baseline to 1 year, the Ki-67 index decreased in the dietary intervention cohort by 15% and increased in the control cohort by 24%. Data from the phase 2 CAPFISH-3 trial show that a high omega-3, ...
Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results